Literature DB >> 27709883

A Unique Mdm2-Binding Mode of the 3-Pyrrolin-2-one- and 2-Furanone-Based Antagonists of the p53-Mdm2 Interaction.

Ewa Surmiak1, Aleksandra Twarda-Clapa2,3, Krzysztof M Zak2,3, Bogdan Musielak1, Marcin D Tomala1, Katarzyna Kubica1, Przemyslaw Grudnik2, Mariusz Madej2,3, Mateusz Jablonski1, Jan Potempa2,3, Justyna Kalinowska-Tluscik1, Alexander Dömling4, Grzegorz Dubin2,3, Tad A Holak1,3.   

Abstract

The p53 pathway is inactivated in almost all types of cancer by mutations in the p53 encoding gene or overexpression of the p53 negative regulators, Mdm2 and/or Mdmx. Restoration of the p53 function by inhibition of the p53-Mdm2/Mdmx interaction opens up a prospect for a nongenotoxic anticancer therapy. Here, we present the syntheses, activities, and crystal structures of two novel classes of Mdm2-p53 inhibitors that are based on the 3-pyrrolin-2-one and 2-furanone scaffolds. The structures of the complexes formed by these inhibitors and Mdm2 reveal the dimeric protein molecular organization that has not been observed in the small-molecule/Mdm2 complexes described until now. In particular, the 6-chloroindole group does not occupy the usual Trp-23 pocket of Mdm2 but instead is engaged in dimerization. This entirely unique binding mode of the compounds opens new possibilities for optimization of the Mdm2-p53 interaction inhibitors.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27709883     DOI: 10.1021/acschembio.6b00596

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  8 in total

1.  A fluorinated indole-based MDM2 antagonist selectively inhibits the growth of p53wt osteosarcoma cells.

Authors:  Lukasz Skalniak; Aleksandra Twarda-Clapa; Constantinos G Neochoritis; Ewa Surmiak; Monika Machula; Aneta Wisniewska; Beata Labuzek; Ameena M Ali; Sylwia Krzanik; Grzegorz Dubin; Matthew Groves; Alexander Dömling; Tad A Holak
Journal:  FEBS J       Date:  2019-02-16       Impact factor: 5.542

2.  Co-operative intra-protein structural response due to protein-protein complexation revealed through thermodynamic quantification: study of MDM2-p53 binding.

Authors:  Sudipta Samanta; Sanchita Mukherjee
Journal:  J Comput Aided Mol Des       Date:  2017-09-04       Impact factor: 3.686

3.  Activity-Directed Synthesis of Inhibitors of the p53/hDM2 Protein-Protein Interaction.

Authors:  Adam I Green; Fruzsina Hobor; Christopher P Tinworth; Stuart Warriner; Andrew J Wilson; Adam Nelson
Journal:  Chemistry       Date:  2020-08-04       Impact factor: 5.236

4.  Scaffold hopping via ANCHOR.QUERY: β-lactams as potent p53-MDM2 antagonists.

Authors:  S Shaabani; C G Neochoritis; A Twarda-Clapa; B Musielak; T A Holak; A Dömling
Journal:  Medchemcomm       Date:  2017-03-15       Impact factor: 3.597

5.  Synthesis and Biological Evaluation of Novel Synthetic Indolone Derivatives as Anti-Tumor Agents Targeting p53-MDM2 and p53-MDMX.

Authors:  Yali Wang; Bo Ji; Zhongshui Cheng; Lianghui Zhang; Yingying Cheng; Yingying Li; Jin Ren; Wenbo Liu; Yuanyuan Ma
Journal:  Molecules       Date:  2022-06-09       Impact factor: 4.927

6.  Experimental and theoretical studies on the synthesis of 1,4,5-trisubstituted pyrrolidine-2,3-diones.

Authors:  Nguyen Tran Nguyen; Vo Viet Dai; Nguyen Ngoc Tri; Luc Van Meervelt; Nguyen Tien Trung; Wim Dehaen
Journal:  Beilstein J Org Chem       Date:  2022-08-31       Impact factor: 2.544

7.  Synthesis and evaluation of the antioxidant activity of 3-pyrroline-2-ones: experimental and theoretical insights.

Authors:  Nguyen Tran Nguyen; Vo Viet Dai; Adam Mechler; Nguyen Thi Hoa; Quan V Vo
Journal:  RSC Adv       Date:  2022-08-30       Impact factor: 4.036

8.  Latency, thermal stability, and identification of an inhibitory compound of mirolysin, a secretory protease of the human periodontopathogen Tannerella forsythia.

Authors:  Krzysztof M Zak; Mark J Bostock; Irena Waligorska; Ida B Thøgersen; Jan J Enghild; Grzegorz M Popowicz; Przemyslaw Grudnik; Jan Potempa; Miroslaw Ksiazek
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.